Phase I pilot study of Wilms tumor gene 1 peptide‐pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|4|397-406

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.4, 2015-04, pp. : 397-406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of weekly nab‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer

By  

Cancer Science, Vol. 106, Iss. 6, 2015-06 ,pp. : 734-739

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 883-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunological evaluation of peptide vaccination for cancer patients with the HLA‐A26 allele

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1257-1263

John Wiley & Sons Inc

Access to resources Recommend Favorite

Personalized peptide vaccination for cervical cancer patients who have received prior platinum‐based chemotherapy

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1111-1117

John Wiley & Sons Inc

Access to resources Recommend Favorite

Personalized peptide vaccination for cervical cancer patients who have received prior platinum‐based chemotherapy

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1111-1117

John Wiley & Sons Inc

Access to resources Recommend Favorite